Akademik Veri Yönetim Sistemi
Discover Oncology, cilt.2025, sa.16 , ss.1-13, 2025 (SCI-Expanded, Scopus)
Abstract Background Uterine leiomyosarcoma is a rare and aggressive malignancy with limited responsiveness to standard therapies. We conducted a real-world, multicenter study to compare the clinical efficacy and safety of two commonly used first-line chemotherapy regimens—doxorubicin–ifosfamide and gemcitabine–docetaxel—in patients with metastatic uterine leiomyosarcoma. Methods This retrospective cohort included 271 patients with advanced or metastatic uterine leiomyosarcoma treated between 2010 and 2023 across 30 centers in Turkey. Patients received either doxorubicin–ifosfamide (n=142) or gemcitabine–docetaxel (n=129) as first-line therapy. The primary endpoint was overall survival; secondary endpoints included progression-free survival, objective response rate, disease control rate, and safety. Adverse events were graded according to the Common Terminology Criteria for Adverse Events version 5.0, while survival outcomes were estimated using the Kaplan–Meier method and further analyzed with Cox proportional hazards models. Results Median overall survival was 19.7 months with doxorubicin–ifosfamide and 20.2 months with gemcitabine–docetaxel (P=.26). Median progression-free survival was 5.5 months with doxorubicin–ifosfamide and 7.0 months with gemcitabine– docetaxel (P=.62). The objective response rate was numerically higher with gemcitabine–docetaxel (35% vs. 26%), although not statistically significant (P=.11)